STAR: A randomised multi-stage phase II/III trial of standard first-line therapy (sunitinib or pazopanib) comparing temporary cessation with allowing continuation, in the treatment of locally advanced and/or metastatic renal Cancer (RCC)

Brown, JE, Royle, K-L orcid.org/0000-0003-0225-1199, Ralph, C et al. (17 more authors) (2021) STAR: A randomised multi-stage phase II/III trial of standard first-line therapy (sunitinib or pazopanib) comparing temporary cessation with allowing continuation, in the treatment of locally advanced and/or metastatic renal Cancer (RCC). In: Annals of Oncology. ESMO Congress 2021, 16-21 Sep 2021, Paris, France. Elsevier , S1303-S1304.

Metadata

Authors/Creators:
Dates:
  • Published: 1 September 2021
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Health Sciences (Leeds) > Academic Unit of Health Economics (Leeds)
The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Health Sciences (Leeds) > Centre for Health Services Research (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 16 Nov 2021 16:46
Last Modified: 16 Nov 2021 16:53
Status: Published
Publisher: Elsevier
Identification Number: https://doi.org/10.1016/j.annonc.2021.08.2104
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Share / Export

Statistics